Endothelial dysfunction determines vascular mechanisms of metastatic progression in breast cancer.

Matluba Mirzaeva, Akbarjon Mirzayev, Bakhtiyar Iriskulov, Sevara B Azimova, Shamsiddin Nizamkhodjaev, Akmal M Asrorov

Abstract readReview

In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matluba MirzaevaTashkent State Medical University, Tashkent, Uzbekistan. matluba.oncologist@gmail.com.ORCID http://orcid.org/0009-0000-3916-3075

Akbarjon MirzayevCentral Asian University, Tashkent, Uzbekistan.ORCID http://orcid.org/0009-0004-3119-8539

Bakhtiyar IriskulovTashkent State Medical University, Tashkent, Uzbekistan.ORCID http://orcid.org/0009-0008-6353-1964

Sevara B AzimovaTashkent State Medical University, Tashkent, Uzbekistan.ORCID http://orcid.org/0000-0003-4449-0622

Shamsiddin NizamkhodjaevKimyo International University in Tashkent, Tashkent, Uzbekistan.ORCID http://orcid.org/0009-0008-2645-9553

Akmal M AsrorovZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Zhongshan, China.ORCID http://orcid.org/0000-0001-5700-1061

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is one of the most common types of cancer among women, leading to death. More than 90% of deaths from BC are due to hematogenous metastases. In the cellular and tissue levels, the aggressiveness of BC is linked with epithelial–mesenchymal transition, leading to enhanced cell motility and spread in the bloodstream, leading to tumor expansion. This review focuses on the vascular mechanisms that facilitate metastatic dissemination in BC, highlighting the influence of blood vessels, hemodynamic forces, and vascular microenvironmental properties on tumor cell spread. Particular emphasis is placed on the role of endothelial dysfunction within common comorbid conditions and how these alterations may increase metastatic propensity. In addition, we discussed whether improving endothelial health and effectively managing comorbidities could help reduce metastatic progression.

Indexed as

Arterial hypertensionBreast cancerDiabetes mellitusEndothelial dysfunctionExtravasationIntravasationMetastases

Identifiers

PMID41546751

DOI10.1007/s12672-026-04437-y

PMCPMC12894596

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.